Cargando…

The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis

BACKGROUND: Apatinib is a small-molecule tyrosine kinase inhibitor targeting VEGFR-2, which was recently used in a phase II clinical trial for the treatment of recurrent or metastatic nasopharyngeal carcinoma (rmNPC). However, there is no consistent conclusion on its efficacy and safety on rmNPC. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Huixiong, Weng, Xiangqian, Wu, Xiangji, Wu, Lizhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273677/ https://www.ncbi.nlm.nih.gov/pubmed/35836539 http://dx.doi.org/10.21037/tcr-22-1467

Ejemplares similares

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
por: Lin, Hao, et al.
Publicado: (2023)

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2020)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma
por: Ma, Huiwen, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
por: Yu, Jiangtao, et al.
Publicado: (2019)

Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
por: Gu, Huiying, et al.
Publicado: (2020)

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
Publicado: (2022)

Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study
por: Liu, Zijing, et al.
Publicado: (2022)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019)

Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review
por: Khan, Aujala Irfan, et al.
Publicado: (2022)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis
por: Gong, Anan, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma
por: Lin, Guohe, et al.
Publicado: (2020)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model
por: Liu, Shanshan, et al.
Publicado: (2020)

Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis
por: Luo, Jian, et al.
Publicado: (2023)

Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review
por: Yan, Le, et al.
Publicado: (2023)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
por: Li, Jianqiang, et al.
Publicado: (2017)

Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review
por: Prawira, A, et al.
Publicado: (2017)

Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma
por: Zhou, Liya, et al.
Publicado: (2020)

Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis
por: Peng, Pei-Jian, et al.
Publicado: (2014)

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis
por: Huang, Xuchen, et al.
Publicado: (2022)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
por: Yuan, Li, et al.
Publicado: (2023)

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
por: Wang, Feng-Hua, et al.
Publicado: (2021)

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
por: Peng, Qiu-Xia, et al.
Publicado: (2017)

Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients
por: Huang, Da, et al.
Publicado: (2022)

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
por: Li, Ningning, et al.
Publicado: (2020)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: Li, Zhe, et al.
Publicado: (2021)

Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2018)

Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer
por: Liu, Haipeng, et al.
Publicado: (2022)

Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis
por: Xue, Jin-min, et al.
Publicado: (2018)

Comparison Efficacy and Safety of Gemcitabine plus Cisplatin and 5-Fluorouracil plus Cisplatin for Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis and Systematic Review
por: Yan, Le, et al.
Publicado: (2022)

Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis
por: Li, Guanglie, et al.
Publicado: (2023)

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study
por: Shi, Yuankai, et al.
Publicado: (2022)

Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
por: Zhao, Jian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g6qd12s8q3aftku8uklv6do1af